News & Media

Recent updates from Arcutis.

February 19, 2020

Arcutis to Present at the Cowen 40th Annual Health Care Conference

February 13, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

February 4, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 30, 2020

Arcutis Announces Pricing of Initial Public Offering

January 15, 2020

Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing

January 13, 2020

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

January 8, 2020

Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque Psoriasis

January 6, 2020

Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

December 16, 2019

Arcutis Announces Top Line Results for Phase 2 Proof-of-Concept Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Atopic Dermatitis

December 5, 2019

Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial

November 14, 2019

Arcutis Appoints Keith Klein as General Counsel

October 30, 2019

Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management Team

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download